Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Amazighon Jun 14, 2021 3:49pm
235 Views
Post# 33383048

RE:RE:RE:RE:RE:Vote No to Reverse Split

RE:RE:RE:RE:RE:Vote No to Reverse Split
I think the following will happen, at least if the RS is accepted by the majority:

-There will be several PR's that will drive the SP up, including a refund of $700000, the start of phase I, and probably some other PR's

-Followed by an RS of 10 to 1 or 20 to 1, depends where the SP is at that moment

-After RS there will be a private placement, and because the price is well above a certain threshold there will be institutional investors involved

-Involvement of institutional investors will drive the SP up

-Announcement of the start of the different cohorts in phase I. The start of the next cohort means that the cohort before was successful. This of course will drive up the SP

-Because CLAS is heavily naked shorted, this will be accompanied by a nice and hopefully epic short squeeze.

In other words, we will never see these low SP levels anymore, SP will be well above $1 (after RS) and probably even more.

When phase II is finished, I cannot imagine where the price will be at that moment.

Of course, this scenario only will happen if RS is accepted and more important phase I is successful.

But again, this is just my opinion
<< Previous
Bullboard Posts
Next >>